EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Vaginal micronized progesterone versus the levonorgestrel‐releasing intrauterine system for treatment of non‐atypical endometrial hyperplasia: A randomized controlled trial

Şener Gezer iD, Emre Köle iD, Lale Aksoy iD

International Journal of Gynecology & Obstetrics · 2023-05 · 161 (2) · 661-666

DOI: 10.1002/ijgo.14632 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 12.01.2023. Verfasst von Şener Gezer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Kocaeli University School of Medicine, Kocaeli, Turkey. Hauptthemen laut MEDLINE: Endometrial Hyperplasia, Intrauterine Devices, Medicated, Menorrhagia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the efficiency of vaginal micronized progesterone (VMP) with the levonorgestrel‐releasing intrauterine system (LNG‐IUS) in patients with non‐atypical endometrial hyperplasia. A validated Menorrhagia Impact Questionnaire (MIQ) was used to assess the quality of life before and after the procedure.

Methods

In this prospective trial, 144 women were randomly assigned to the VMP or LNG‐IUS group. The primary endpoint was the regression rate of endometrial hyperplasia after 3 months of treatment. The protocol was approved by the institutional ethics committee and registered at ClinicalTrials.gov (NCT03992937).

Results

In all, 138 patients were analyzed. The regression rate was not significantly different between the groups (95.8% with LNG‐IUS vs. 90.8% with VMP; P = 0.194). Differences between pre‐ and post‐treatment MIQ scores were similar, except that better scores were obtained in the VMP group for the perception of the amount of blood loss ( P = 0.035).

Conclusion

VMP is as effective as the LNG‐IUS as a local treatment of endometrial hyperplasia without atypia. Trial registration https://clinicaltrials.gov/ct2/show/NCT03992937 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial HyperplasiaIntrauterine Devices, MedicatedMenorrhagiaHumansFemaleProgesteroneLevonorgestrelProspective StudiesQuality of Life

Stichwörter der Autor:innen

Bayerlevonorgestrel-releasing intrauterine systemnon-atypical endometrial hyperplasiavaginal micronized progesterone

Substanzen

ProgesteroneLevonorgestrel

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Kocaeli University School of Medicine, Kocaeli, Turkey.
  • Department of Obstetrics and Gynecology, Alanya Alaaddin Keykubat University School of Medicine, Alanya, Turkey.
  • Department of Obstetrics and Gynecology, Geyve State Hospital, Geyve, Turkey.

ORCID-Profile: Şener Gezer, Emre Köle, Lale Aksoy

Zitieren

APA

Gezer, Ş., Köle, E., & Aksoy, L. (2023). Vaginal micronized progesterone versus the levonorgestrel‐releasing intrauterine system for treatment of non‐atypical endometrial hyperplasia: A randomized controlled trial. International Journal of Gynecology & Obstetrics, 161(2), 661-666. https://doi.org/10.1002/ijgo.14632

Vancouver

Gezer Ş, Köle E, Aksoy L. Vaginal micronized progesterone versus the levonorgestrel‐releasing intrauterine system for treatment of non‐atypical endometrial hyperplasia: A randomized controlled trial. International Journal of Gynecology & Obstetrics. 2023;161(2):661-666. doi:10.1002/ijgo.14632

BibTeX
@article{Gezer2023,
  author = {Gezer, Şener and Köle, Emre and Aksoy, Lale},
  title = {Vaginal micronized progesterone versus the levonorgestrel‐releasing intrauterine system for treatment of non‐atypical endometrial hyperplasia: A randomized controlled trial},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2023},
  volume = {161},
  number = {2},
  pages = {661--666},
  doi = {10.1002/ijgo.14632}
}
Kostenlos starten →